Kyorin Pharmaceutical said on March 31 that it has exercised an option on France-based BIODOL Therapeutics’ neuropathic pain candidate BDT272 and entered into a new license agreement for the asset. Under the deal, Kyorin obtains the exclusive rights to develop,…
To read the full story
Related Article
- Kyorin, Biodol Ink Option Deal for Novel Pain Drug
January 15, 2025
BUSINESS
- Shionogi/F2G’s Novel Antifungal Makes Mark, New Option in Resistant Cases
June 19, 2026
- Axcelead Joins Lilly’s TuneLab AI Drug Discovery Platform
June 19, 2026
- Create BioVentures Sets Sail as Drug Discovery Bridge Builder
June 19, 2026
- Merck Japan Expands Fertility Benefits, Raises Lifetime Cap to 18 Million Yen
June 19, 2026
- Santen CEO Paid 251 Million Yen in FY2025, COO Joins Disclosure List
June 19, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





